Bellwether Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bellwether Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37	Closed	-$16.5K	–	561
2025 Q2	$16.5K	Hold	37	–	–	﹤0.01%	321
2025 Q1	$17.9K	Hold	37	–	–	﹤0.01%	280
2024 Q4	$14.9K	Buy	+37	New	+$17.2K	﹤0.01%	306
2024 Q2	–	Sell	-10,280	Closed	-$4.3M	–	139
2024 Q1	$4.3M	Sell	10,280 -8,971	-47%	-$3.79M	0.94%	27
2023 Q4	$7.83M	Buy	+19,251	New	+$7.11M	1.93%	10
2023 Q2	–	Sell	-25	Closed	-$7.88K	–	438
2023 Q1	$7.88K	Hold	25	–	–	﹤0.01%	287
2022 Q4	$7.22K	Hold	25	–	–	﹤0.01%	289
2022 Q3	$7K	Buy	+25	New	+$7.19K	﹤0.01%	299

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellwether Advisors's VRTX Position: Q3 2025 in Review

Bellwether Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 37 shares — an estimated $16.5K sold.

Bellwether Advisors first reported a position in VRTX in Q3 2022 and held it in 8 quarters. The position peaked at $7.83M in Q4 2023. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Bellwether Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Bellwether Advisors sold 37 Vertex Pharmaceuticals shares in Q3 2025, an estimated $16.5K.
Bellwether Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 8 quarters.
Bellwether Advisors's Vertex Pharmaceuticals position peaked at $7.83M in Q4 2023.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Bellwether Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.